Journal of Medicinal Chemistry · 2014 · 40 citations · 44 references
Life SciencesImmunologyMedicinal ChemistryInflammationInnate ImmunityVaccine ImmunologyAdjuvant DesignInnate Immune ReceptorsInnate Immune ResponseInnate Immune Signaling PathwaysInterferon ResponsesToll-like ReceptorsChemical Structure-activity RelationshipsStructure-based Ligand DesignToll-like Receptor LigandsToll-like Receptor SignalingToll-like Receptor-mediated Cytokine InductionType Ii Interferon ResponseType Ii Interferon SignalingVaccine Adjuvant Development
Toll-like receptor (TLR)-8 agonists strongly induce the production of T helper 1-polarizing cytokines and may therefore serve as promising candidate vaccine adjuvants, especially for the very young and the elderly. Earlier structure-based ligand design led to the identification of 3-pentyl-quinoline-2-amine as a novel, human TLR8-specific agonist. Comprehensive structure-activity relationships in ring-contracted 1-alkyl-1H-benzimidazol-2-amines were undertaken, and the best-in-class compound, 4-methyl-1-pentyl-1H-benzo[d]imidazol-2-amine, was found to be a pure TLR8 agonist, evoking strong proinflammatory cytokine and Type II interferon responses in human PBMCs, with no attendant CD69 upregulation in natural lymphocytic subsets. The 1-alkyl-1H-benzimidazol-2-amines represent a novel, alternate chemotype with pure TLR8-agonistic activities and will likely prove useful not only in understanding TLR8 signaling but also perhaps as a candidate vaccine adjuvant.
44
Aluminum compounds as vaccine adjuvants
Advanced Drug Delivery Reviews · 1998 · 626 citations
Neonatal Innate TLR-Mediated Responses Are Distinct from Those of Adults
Tobias R. Kollmann, Juliet Crabtree, Annie Rein‐Weston et al. · The Journal of Immunology · 2009 · 462 citations · Full text